Robins' Dalkon Shield notification program
Executive Summary
Firm alerting users of the intrauterine device that April 30 is deadline for filing claims of injury linked to use of the device. Program will run Jan. 6-25 and will include print ads in 225 newspapers and several national weekly magazines and 30-second television spots broadcast by network and cable stations. Projecting costs of $5 mil., Robins will also issue news releases, public service announcements, and letters to foreign health officials in approximately 80 countries.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.